ZLDPF Zealand Pharma A/S

Correction: Zealand Pharma convenes its Annual General Meeting 2023

Correction: Zealand Pharma convenes its Annual General Meeting 2023

Correction: Company Announcement – No. 2 / 2023

Zealand convenes its Annual General Meeting 2023



 



Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").
 
The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:
 
Wednesday, March 29 2023 at 3:00 pm (CEST)



 
The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting).
 
The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Søborg. 
 
Please find further information in the updated accompanying attachment [item 3, page 2 corrected loss figure].

Attachment



EN
03/03/2023

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

February 19, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...

Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...

ZLDPF ZEALAND PHARMA A/S
02/19/26 February 19, 2026 1 EN
Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
ENX EURONEXT NV
MTLS MATERIALISE ADS ... (+13)

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

ENX EURONEXT NV
MTLS MATERIALISE ADS
GIMB GIMV NV
IBAB ION BEAM APPLICATIONS SA
ARCAD ARCADIS NV
ZLDPF ZEALAND PHARMA A/S
VGP VGP NV
KIN KINEPOLIS GROUP NV
ABI ANHEUSER-BUSCH INBEV SA/NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
HYL HYLORIS PHARMACEUTICALS
AZE AZELIS GROUP NV
AGN AEGON N.V.
02/19/26 February 19, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Financial Results for the Full Year 2025

Zealand Pharma Announces Financial Results for the Full Year 2025 Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading...

February 19, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker

Zealand Pharma reported positive phase 1a topline results for the Kv1.3 channel blocker ZP9830. Single ascending doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings, and PK/PD profile was in-line with predictions. We view these data as de-risking for the program and look forward to the MAD data expected in 2H26, which should provide insight into extended exposure and additional proof of mechanism. Given the selective expression of Kv1.3 ...

ZLDPF ZEALAND PHARMA A/S
02/18/26 February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch